StockData
Aktis Oncology, Inc. logo

Aktis Oncology, Inc. (AKTS) stock

AKTSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$16.10−0.21 (-1.29%)

Close on Nov 18, 2026Market cap $895.47MP/E –Yield –

Aktis Oncology operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$34.75M–
Q2 FY2026Jun 30, 2026-$28.90M–
Q1 FY2026Mar 31, 2026-$22.71M–
Q3 FY2025Sep 30, 2025-$18.20M–
Q2 FY2025Jun 30, 2025-$20.96M–
Q1 FY2025Mar 31, 2025-$18.14M–

More Aktis Oncology figures

See a number that looks wrong?